Latest Novocure News & Updates

See the latest news and media coverage for Novocure. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Novocure

Oncology medical device company

novocure.com
Headquarters
Baar, Switzerland
Founded year
2000
Company type
Public company
Number of employees
1,500–5,000

Last updated

Latest news about Novocure

In short: Novocure launched Optune Pax following FDA approval for pancreatic cancer and reported Q1 2026 revenues of $174 million, a 12% year-over-year increase.

Company announcements

Novocure

Novocure reports Q1 2026 financial results

Net revenues reach $174 million, up 12% year-over-year. Optune Pax gains FDA approval and launches for pancreatic cancer. Active patients total 4,791 globally.

Novocure

Novocure announces positive topline results from PANOVA-4 trial

The Phase 2 trial met its primary endpoint with 74.4% disease control rate in metastatic pancreatic cancer patients treated with TTFields plus chemotherapy, exceeding historical control. Novocure plans future presentations.

Unlock all announcements with a

Media coverage

Aktien-Check

NovoCure stock: Optune Pax approved

NovoCure stock rises over 13 percent to 15.41 euros on Thursday. The medical technology specialist benefits from several positive developments from the clinical...

Bez Kabli

NovoCure Stock Still Up Ahead of Cancer Trial Data

Small move, but the timing stands out. NovoCure shares are holding around 50% higher than where they closed on April 29, right before the cancer...

Unlock all articles with a

Never miss news about Novocure

Track Novocure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Novocure competitors & trending companies

Browse news for competitors to Novocure and other trending companies.